{
    "nctId": "NCT06341283",
    "briefTitle": "A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer",
    "officialTitle": "A Retrospective Real-world Study of Efficacy, Safety, and Economic Assessment of Abemaciclib Tablets Based on Hospital Information System(HIS) in Hormone Recepter Positive(HR+) Breast Cancer Patients",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer, Neoplasms, Breast Diseases",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Progression-free survival(PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years or older\n* Histologically confirmed HR-positive breast cancer and Imaging/pathological evidence of metastasis is available\n* Treatment with abemaciclib in combination with endocrine therapy\n* Any endocrine therapy\n* Having solid tumor efficacy evaluation criteria RECIST 1.1 measurable lesions\n\nExclusion Criteria:\n\n* Combined with other primary malignancies\n* Associated with serious non-tumor related diseases, such as cardiovascular system, respiratory system, nervous system, blood system, digestive system\n* Pregnant or lactating women\n* male breast cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}